MAR 13, 2015 04:44 PM PDT

A Good Night's Sleep Does More Than Prevent Yawning

New research from The Scripps Research Institute (TSRI) shows that two proteins critical for maintaining healthy day-night cycles also protect against mutations that could lead to cancer.

The new study, published March 10, 2015, in the journal eLife, shows that the two proteins have an unexpected role in DNA repair, possibly protecting cells from cancer-causing mutations triggered by UV radiation.

"These proteins play an important role in the response to DNA damage," said TSRI biologist Katja Lamia, senior author of the study. "Researchers might eventually harness that knowledge for pharmaceutical targeting."

Day and Night

The human body senses light and adjusts its rhythms to a day-night cycle called the circadian clock. Feeling tired? Feeling hungry? These feelings are strongly influenced by the body's circadian clock.

Studies show that people with unusual sleep schedules, such as flight attendants or night-shift nurses, are at risk for certain health problems.

"When you have a deregulation of your circadian clock, you're more prone to develop some kind of pathology, like diabetes, cancer or heart disease," said TSRI Research Associate Anne-Laure Huber, who was co-first author of the study with Stephanie Papp, a graduate student at TSRI.

In the new study, the research team investigated a possible cause of these health disparities. They focused on the role of proteins called cryptochromes, which are believed to have evolved from light-activated DNA repair enzymes in bacteria.

Cryptochromes contain a photo-responsive pigment called flavin. While cryptochromes are no longer light-activated, they do hold to a daytime-regulated schedule, and stability of the proteins cryptochrome 1 (Cry1) and cryptochrome 2 (Cry2) is critical for circadian clock function. In the human body, cryptochromes no longer have a direct role in DNA repair either, but they are essential for regulating blood sugar levels and protein production on a day-night cycle.

Repairing DNA

The new study started when the researchers went on what Lamia calls a "fishing expedition." They used a technique called proteomic screening, in collaboration with the laboratory of TSRI Professor John Yates, to test for a wide range of proteins that could bind to Cry1 or Cry2 from mouse and human cells.

The team found that Cry1 could bind with Hausp, a protein with a known role in regulating an anti-cancer protein called p53. The screening also showed that Hausp binds to Cry2, but not as strongly, suggesting that the nearly identical proteins actually have different roles related to DNA repair.

"Most of the time people study them as redundant proteins, but we show that they have distinct functions in this DNA-repair pathway," said Lamia.

Subsequent studies of genetic expression showed that Hausp stabilizes Cry1 by removing protein chains that trigger Cry1 degradation. By stabilizing Cry1, Hausp prevents potential errors in DNA transcription that could occur when DNA is exposed to radiation.

"This is very cool," said Papp. "These proteins can sense that something is wrong in the cells."

The researchers also found that when they blocked Cry2 production in cells, the cells no longer activated p21, a protein that stops mutant cells from dividing. "This could suggest that cells without Cry2 would be more susceptible to cancer," said Lamia.

Together, these findings show that while Cry1 and Cry2 no longer directly repair DNA, they still have an indirect role in the repair process.

This new link between circadian clock proteins and DNA repair is a clue to how disrupting day-night cycles could harm health. Lamia said future studies in her lab will explore additional roles of cryptochromes in the body.

Source: TSRI
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 22, 2019
Neuroscience
SEP 22, 2019
How to dial up or down emotional memories
Memories of traumatic experiences can resurface over and over again, causing great emotional distress. This is a hallmark symptom of psychiatric diseases such as PTSD, anxiety, and depression...
SEP 22, 2019
Health & Medicine
SEP 22, 2019
Mighty Multitasker, Mitochondria Do More Than Power The Cell
We all remember the mighty mitochondria from high school biology. These cellular power-houses are best known for their role in energy production. Specifica...
SEP 22, 2019
Genetics & Genomics
SEP 22, 2019
Research Reveals Role of Leptin in Human Appetite
  A drop in leptin concentration, a hormone released from fat stores, was vaguely understood to influence increased appetite.  New research out o...
SEP 22, 2019
Drug Discovery & Development
SEP 22, 2019
Can Ecstasy Treat PTSD and Depression?
Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depr...
SEP 22, 2019
Neuroscience
SEP 22, 2019
Does free will exist? Neuroscientists debunk popular argument against free will
For decades, a groundbreaking brain study fueled opinions about whether we have free will over our actions. The conclusions drawn from this experiment, how...
SEP 22, 2019
Neuroscience
SEP 22, 2019
Can CRISPR Technology Treat Alzheimer's?
New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that ca...
Loading Comments...